Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane

Clinical trial NCT00036270 · COMPLETED

Trial details

NCT number: NCT00036270
Sponsor: Pfizer
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Breast Neoplasms

Start date: 2001-08-01
Primary completion: 2008-10-01
Enrollment: 9779

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.